Bristol-Myers Squibb market cap BMY
Share price times shares outstanding: what the whole company sells for, since 2009.
- Today, Oct 23, 2026
- $125.6B
- Highest close in our data
- $172.5B
- Dec 2022
Bristol-Myers Squibb is worth $125.6B at the close on Oct 23, 2026, at $61.48 a share.
That is up 41% over the last year and down 3% over five years.
Its highest close in our data was $172.5B in Dec 2022.
Market cap over time
Year by year
| Year | End of year | Low | High | Change |
|---|---|---|---|---|
| 2026 so far | $125.6B | $108.8B | $136.9B | +13% |
| 2025 | $111.2B | $88.8B | $124B | −5% |
| 2024 | $117B | $80.4B | $120.4B | +12% |
| 2023 | $104.4B | $101.2B | $158.3B | −32% |
| 2022 | $153B | $139.5B | $172.5B | +11% |
| 2021 | $138.4B | $125B | $153.8B | −1% |
| 2020 | $140.2B | $102.3B | $145B | +34% |
| 2019 | $104.5B | $70.9B | $104.5B | +26% |
| 2018 | $83.1B | $81.3B | $112.6B | −17% |
| 2017 | $100.3B | $79.8B | $107.1B | +3% |
| 2016 | $97.7B | $83.2B | $126.9B | −15% |
| 2015 | $114.8B | $95.5B | $115.5B | +16% |
| 2014 | $98.8B | $78B | $101.7B | +13% |
| 2013 | $87.5B | $55.1B | $87.9B | +66% |
| 2012 | $52.7B | $52.3B | $60.7B | −12% |
| 2011 | $59.7B | $43.2B | $59.7B | +32% |
| 2010 | $45.3B | $38.6B | $49.7B | −9% |
| 2009 | $50B | $42.4B | $51.1B | n/a |
Against its peers
Companies in Drug Manufacturers - General nearest Bristol-Myers Squibb's size, closest first, today.
| Company | Market cap |
|---|---|
| BMYBristol-Myers Squibb | $125.6B |
| PFEPfizer | $171.2B |
| GILDGilead Sciences | $193.5B |
| AMGNAmgen | $237.5B |
| MRKMerck | $358.4B |
| BIIBBiogen | $37B |
| ABBVAbbVie | $504.8B |
| JNJJohnson & Johnson | $635.8B |
| JAZZJazz Pharmaceuticals | $13.9B |
| LLYEli Lilly and | $1.2T |
| Peer median | $237.5B |
What the market cap tells you
Share price times shares outstanding: what the whole company sells for today.
Size, not quality. Large caps move slower and are covered more. That is all it tells you.
More on Bristol-Myers Squibb
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.